指南与共识白血病

迈向基于基因组的急性髓系白血病分类:WHO-HAEM4R、WHO-HAEM5与国际共识分类的比较分析

Advances towards genome-based acute myeloid leukemia classification: A comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification.
指南 / 共识 · Am J Hematol · 2024-02-06

本研究比较了1135例急性髓系白血病(AML)在WHO-HAEM5与ICC两种新标准下的分类。整合全转录组测序、靶向基因突变筛查和常规细胞遗传学分析后,WHO-HAEM5与ICC分别可在89%和90%的AML患者中识别出定义性遗传学异常;两种标准分类结果在16%的AML病例中存在差异,且均显著减少了仅由形态学和分化程度定义的病例数。

要点

  • WHO-HAEM5与ICC分别可在89%和90%的AML患者中识别定义性遗传学异常。
  • 两种新标准分类结果在16%的AML病例中存在差异。
  • 两种新标准均显著减少仅由形态学和分化程度定义的AML病例数。

核心结论

  • WHO-HAEM5与ICC均更广泛地考虑基因组特征并扩展了分子定义的AML亚型,但二者在16%的AML病例中分类不一致。
  • 两种新标准的临床实施高度依赖全面的基因组分析,包括基因组与转录组水平以及致病性体细胞和胚系变异的评估。
  • RUNX1突变的归属、将TP53突变型AML设为独立实体的合理性、罕见遗传融合的范围以及同时存在的AML定义性遗传学异常的优先级等问题仍待进一步研究。

研究设计与样本

  • 本研究比较了1135例AML病例在WHO-HAEM5与ICC两种标准下的分类。
  • 分类整合了全转录组测序、靶向基因突变筛查和常规细胞遗传学分析。

主要发现

  • 根据WHO-HAEM5与ICC,整合全转录组测序、靶向基因突变筛查和常规细胞遗传学分析分别在89%和90%的AML患者中识别出定义性遗传学异常。
  • 分别使用两种指南分类后,16%的AML病例分类结果存在差异。
  • 两种新标准均显著减少了由形态学和分化程度定义的病例数。

关键数值与推荐

  • WHO-HAEM5识别定义性遗传学异常的比例为89%,ICC为90%。
  • WHO-HAEM5与ICC分类结果存在差异的AML病例占16%。

临床怎么用

  • 两种新标准的临床实施高度依赖全面的基因组分析,包括基因组与转录组水平以及致病性体细胞和胚系变异的评估。

局限性

  • WHO-HAEM5与ICC在RUNX1突变归属、TP53突变型AML作为独立实体的合理性、罕见遗传融合的范围以及同时存在的AML定义性遗传学异常的优先级等方面仍存在差异,属待进一步研究的问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Two recent guidelines, the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO-HAEM5) and the International Consensus Classification (ICC), were published to refine the diagnostic criteria of acute myeloid leukemia (AML). They both consider genomic features more extensively and expand molecularly defined AML subtypes. In this study, we compared the classifications of 1135 AML cases under both criteria. According to WHO-HAEM5 and ICC, the integration of whole transcriptome sequencing, targeted gene mutation screening, and conventional cytogenetic analysis identified defining genetic abnormalities in 89% and 90% of AML patients, respectively. The classifications displayed discrepancies in 16% of AML cases after being classified using the two guidelines, respectively. Both new criteria significantly reduce the number of cases defined by morphology and differentiation. However, their clinical implementation heavily relies on comprehensive and sophisticated genomic analysis, including genome and transcriptome levels, alongside the assessment of pathogenetic somatic and germline variations. Discrepancies between WHO-HAEM5 and ICC, such as the assignment of RUNX1 mutations, the rationality of designating AML with mutated TP53 as a unique entity, and the scope of rare genetic fusions, along with the priority of concurrent AML-defining genetic abnormalities, are still pending questions requiring further research for more elucidated insights.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Chen X, Yuan L, Zhang Y, et al. Advances towards genome-based acute myeloid leukemia classification: A comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification. Am J Hematol. 2024. PMID: 38321864. doi:10.1002/ajh.27249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。